Siremadlin
Tier C — Watch / tradeSiremadlin
Targets：MDM2
Indications (approved)：Sarcoma, Haematological malignancy, Hepatic function decline, Acute myeloid leukaemia, Colorectal cancer, Metastatic cancer, Myelofibrosis, Myelodysplastic syndrome
Regional status
Synthetic routes & intermediates1 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| HDM-201 | - | (S)-5-(5-chloro-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)-6-(4-chlorophenyl)-2-(2,4-dimethoxypyrimidin-5-yl)-1-isopropyl-5,6-dihydropyrrolo[3,4-d]imidazol-4(1H)-one |
| HDM-201-001 | 105-56-6Available | ethyl 2-cyanoacetate |
| HDM-201-002 | 1188-33-6 | 1,1-diethoxy-N,N-dimethylmethanamine |
| HDM-201-003 | 57338-21-3 | ethyl (E)-2-cyano-3-(dimethylamino)acrylate |
| HDM-201-004 | 1260793-84-7 | ethyl 1-isopropyl-1H-imidazole-4-carboxylate |
| HDM-201-005 | 1448869-67-7 | ethyl 2-bromo-1-isopropyl-1H-imidazole-4-carboxylate |
| HDM-201-006 | 104-88-1 | 4-chlorobenzaldehyde |
| HDM-201-007 | 1448869-68-8 | ethyl 2-bromo-5-((4-chlorophenyl)(hydroxy)methyl)-1-isopropyl-1H-imidazole-4-carboxylate |
| HDM-201-008 | 1441769-24-9 | 3-amino-5-chloro-1-methylpyridin-2(1H)-one |
| HDM-201-009 | 1448870-71-0 | ethyl 2-bromo-5-(((5-chloro-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)amino)(4-chlorophenyl)methyl)-1-isopropyl-1H-imidazole-4-carboxylate |
| HDM-201-010 | 1448870-70-9 | 2-bromo-5-(((5-chloro-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)amino)(4-chlorophenyl)methyl)-1-isopropyl-1H-imidazole-4-carboxylic acid |
| HDM-201-011 | 1448870-69-6 | 2-bromo-5-(5-chloro-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)-6-(4-chlorophenyl)-1-isopropyl-5,6-dihydropyrrolo[3,4-d]imidazol-4(1H)-one |
| HDM-201-012 | - | (2,4-dimethoxypyrimidin-5-yl)boronic acid |
| HDM-201-013 | 1448867-40-0 | 5-(5-chloro-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)-6-(4-chlorophenyl)-2-(2,4-dimethoxypyrimidin-5-yl)-1-isopropyl-5,6-dihydropyrrolo[3,4-d]imidazol-4(1H)-one |
| HDM-201-014 | 21427-61-2 | 5-chloro-3-nitropyridin-2-ol |
| HDM-201-015 | 170661-48-0 | 5-chloro-1-methyl-3-nitropyridin-2(1H)-one |
Frequently asked questions
What are the approved indications of Siremadlin?
Approved indications include: Sarcoma, Haematological malignancy, Hepatic function decline, Acute myeloid leukaemia, Colorectal cancer, Metastatic cancer, Myelofibrosis, Myelodysplastic syndrome.
When does the Siremadlin patent expire?
No public expiry year is available for Siremadlin yet; this page updates once verified.
How many synthesis routes are recorded for Siremadlin?
1 synthesis routes are recorded; the shortest is 11 steps with / total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Siremadlin intermediates?
1 intermediate CAS of Siremadlin are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for Siremadlin intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-07